Journal ArticleDOI
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristiansson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel +14 more
TLDR
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.About:
This article is published in The Lancet.The article was published on 2002-03-23. It has received 5380 citations till now. The article focuses on the topics: Angiotensin II & Atenolol.read more
Citations
More filters
Journal ArticleDOI
Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.
Active W Investigators,Stuart J. Connolly,Salim Yusuf,A Budaj,John Camm,Susan Chrolavicius,Patrick J. Commerford,Marcus Flather,Keith A.A. Fox,Robert G. Hart,S H Hohnloser,Campbell D. Joyner,Marc A. Pfeffer,Inderjit Anand,Heather M. Arthur,A Avezum,M Bethala-Sithya,Mel Blumenthal,L Ceremuzynski,R. De Caterina,Rafael Diaz,Gregory C. Flaker,G Frangin,M-G Franzosi,Christophe Gaudin,Sergey P. Golitsyn,Samuel Z. Goldhaber,Christopher B. Granger,David A. Halon,Antonio G. Hermosillo,David M. Hunt,Petr Jansky,Nicholas Karatzas,Matyas Keltai,Fernando Lanas,C P Lau,J-Y Le Heuzey,Basil S. Lewis,João Morais,Carlos A. Morillo,Ali Oto,Ernesto Paolasso,Ron J.G. Peters,M Pfisterer,Leopoldo S. Piegas,T Pipillis,C Proste,Eva Sitkei,Karl Swedberg,David Synhorst,Mario Talajic,V Trégou,Vicent Valentin,W. Van Mieghem,William S. Weintraub,John Varigos +55 more
TL;DR: Clopidogrel plus ASA plus irbesartan will lead to a new understanding of the role of combined antiplatelet therapy and therole of blood pressure lowering with an angiotensin II receptor blocker in patients with AF.
Journal ArticleDOI
Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
Elsayed Z. Soliman,Walter T. Ambrosius,William C. Cushman,Zhu Ming Zhang,Jeffrey T. Bates,Javier A. Neyra,Javier A. Neyra,Thaddeus Y. Carson,Leonardo Tamariz,Lama Ghazi,Monique E. Cho,Brian P. Shapiro,Jiang He,Lawrence J. Fine,Cora E. Lewis +14 more
TL;DR: In this paper, it was shown that intensive blood pressure lowering beyond that recommended would lead to more lowering of the risk of left ventricular hypertrophy (LVH) in patients w...
Journal ArticleDOI
[Guidelines for diagnosis and treatment of chronic coronary heart disease. Issued by the executive committee of the German Society of Cardiology--Heart Circulation Research in cooperation with the German Society for Prevention and Rehabilitation of Cardiac Diseases and the German Society for Thoracic and Cardiovascular Surgery].
Rainer Dietz,B. Rauch +1 more
TL;DR: 3.2.2 Risikofaktoren-Management und Pravention werden €3.3.1 Vorbemerkungen .
Journal ArticleDOI
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk
Stevo Julius,Sverre E. Kjeldsen,Hans R. Brunner,Lennart Hansson,Francis Platt,Steffan Ekman,John H. Laragh,Gordon T. McInnes,Anthony Schork,Beverly Smith,Michael A. Weber,Alberto Zanchetti +11 more
TL;DR: The VALUE study is executed in regular clinical settings and 92% of the patients received antihypertensive drugs at baseline and the achieved BP control exceeds values reported in most published large-scale trials.
Journal ArticleDOI
Fetal stress and programming of hypoxic/ischemic-sensitive phenotype in the neonatal brain: mechanisms and possible interventions.
TL;DR: This review summarizes the recent studies about the effects of fetal stress on the abnormal brain development, focusing on the cellular, molecular and epigenetic mechanisms and highlighting the central effects of glucocorticoids on programming of hypoxic-ischemic-sensitive phenotype in the neonatal brain, which may enhance the understanding of brain pathophysiology resulting from fetal stress.
References
More filters
Journal ArticleDOI
Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
TL;DR: Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
Journal ArticleDOI
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Barry M. Brenner,Mark E. Cooper,Dick de Zeeuw,William F. Keane,William E. Mitch,Hans-Henrik Parving,Giuseppe Remuzzi,Steven M. Snapinn,Zhonxin Zhang,Shahnaz Shahinfar +9 more
TL;DR: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Journal ArticleDOI
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Lennart Hansson,Lars H Lindholm,Leo Niskanen,Jan Lanke,Thomas Hedner,Anders Niklason,Kimmo Luomanmäki,Björn Dahlöf,Ulf de Faire,Claes Mörlin,Bengt E. Karlberg,P. O. Wester,Jan-Erik Björck +12 more
TL;DR: Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality and the difference in stroke risk was probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy.
Journal ArticleDOI
An updated coronary risk profile. A statement for health professionals.
TL;DR: Using a simple worksheet, a patient's 5- and 10-year CHD risks can be estimated using components of the profile selected because they are objective and strongly and independently related to CHD.
Journal ArticleDOI
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration
TL;DR: Strong evidence of benefits of ACE inhibitors and calcium antagonists is provided by the overviews of placebo-controlled trials, and data from continuing trials of blood-pressure-lowering drugs will substantially increase the evidence available about any real differences that might exist between regimens.
Related Papers (5)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Curt D. Furberg,Jackson T. Wright,Barry R. Davis,Jeffrey A. Cutler,Michael H. Alderman,Henry R. Black,William C. Cushman,Richard H. Grimm,L. Julian Haywood,Frans H. H. Leenen,Suzanne Oparil,Jeffrey L. Probstfield,Paul K. Whelton,Chuke Nwachuku,David Gordon,Michael A. Proschan,Paula Einhom,Charles E. Ford,Linda B. Piller,I. Kay Dunn,David C. Goff,Sara L. Pressel,Judy Bettencourt,Barbara DeLeon,Lara M. Simpson,Joe Blanton,Therese S. Geraci,Sandra M. Walsh,Christine Nelson,Mahboob Rahman,Anne Juratovac,Robert Pospisil,Lillian Carroll,Sheila Sullivan,Jeanne Russo,Gail Barone,Rudy Christian,Sharon Feldman,Tracy Lucente,David A. Calhoun,Kim Jenkins,Peggy McDowell,Janice Johnson,Connie Kingry,Juan Alzate,Karen L. Margolis,Leslie Ann Holland-Klemme,Brenda Jaeger,Jeff D. Williamson,Gail T. Louis,Pamela Ragusa,Angela Williard,R. L Sue Ferguson,Joanna Tanner,John H. Eckfeldt,Richard S. Crow,John Pelosi +56 more